Independent prognostic variables in acute myeloid leukaemia

Blood Reviews

Volumn 25, Issue 1, 2011, Pages 39-51

  Smith, Matthew L ^a   Hills, Robert K ^b   Grimwade, David ^c  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^b CARDIFF UNIVERSITY   (United Kingdom)

^c GUY S HOSPITAL   (United Kingdom)

Author keywords

AML; CEBPA; Cytogenetics; FLT3; IDH; Minimal residual disease; Nucleophosmin

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE; ANTIMETABOLITE; CCAAT ENHANCER BINDING PROTEIN; CYTARABINE; EPIRUBICIN; FLT3 LIGAND; GYRASE INHIBITOR; ISOCITRATE DEHYDROGENASE; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN 1; NUCLEOPHOSMIN; STEM CELL FACTOR; TRANSCRIPTION FACTOR RUNX1;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CYTOGENETICS; GENE MUTATION; GENE OVEREXPRESSION; GENETIC HETEROGENEITY; HUMAN; KARYOTYPE; MORTALITY; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; SURVIVAL RATE; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LEUKEMIA, MYELOID, ACUTE; PROGNOSIS;

EID: 78649905124     PISSN: 0268960X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.blre.2010.10.002     Document Type: Article

References (182)

1. Hiddemann W., Kern W., Schoch C., et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol 1999, 17(11):3569-3576.
2. Appelbaum F.R., Gundacker H., Head D.R., et al. Age and acute myeloid leukemia. Blood 2006, 107(9):3481-3485.
3. Sekeres M.A., Stone R.M. The challenge of acute myeloid leukemia in older patients. Curr Opin Oncol 2002, 14(1):24-30.
4. Burnett A.K., Hills R.K., Milligan D.W., et al. Attempts to optimize induction and consolidation treatment in acute myeloid leukemia: results of the MRC AML12 trial. J Clin Oncol 2010, 28(4):586-595.
5. Burnett A.K., Milligan D., Goldstone A., et al. The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial. Br J Haematol 2009, 145(3):318-332.
6. Wheatley K., Burnett A.K., Goldstone A.H., et al. A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial. United Kingdom Medical Research Council's Adult and Childhood Leukaemia Working Parties. Br J Haematol 1999, 107(1):69-79.
7. Giles F.J., Borthakur G., Ravandi F., et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol 2007, 136(4):624-627.
8. Sorror M.L., Giralt S., Sandmaier B.M., et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. Blood 2007, 110(13):4606-4613.
9. Dalley C.D., Lister T.A., Cavenagh J.D., et al. Serum LDH, a prognostic factor in elderly patients with acute myelogenous leukaemia. Br J Cancer 2001, 84(1):147.
10. Martin G., Barragan E., Bolufer P., et al. Relevance of presenting white blood cell count and kinetics of molecular remission in the prognosis of acute myeloid leukemia with CBFbeta/MYH11 rearrangement. Haematologica 2000, 85(7):699-703.
11. Nguyen S., Leblanc T., Fenaux P., et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood 2002, 99(10):3517-3523.
12. Burnett A.K., Grimwade D., Solomon E., et al. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 1999, 93(12):4131-4143.
13. Greenwood M.J., Seftel M.D., Richardson C., et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leuk Lymphoma 2006, 47(7):1245-1252.
14. Larson R.A. Is secondary leukemia an independent poor prognostic factor in acute myeloid leukemia?. Best Pract Res Clin Haematol 2007, 20(1):29-37.
15. Pedersen-Bjergaard J., Andersen M.K., Christiansen D.H., et al. Genetic pathways in therapy-related myelodysplasia and acute myeloid leukemia. Blood 2002, 99(6):1909-1912.
16. Pedersen-Bjergaard J., Andersen M.K., Andersen M.T., et al. Genetics of therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008, 22(2):240-248.
17. Swerdlow S.H., Campo E., Harris N.L., et al. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, IARC, Lyon. 4th ed.
18. Carli P.M., Sgro C., Parchin-Geneste N., et al. Increase therapy-related leukemia secondary to breast cancer. Leukemia 2000, 14(6):1014-1017.
19. Beaumont M., Sanz M., Carli P.M., et al. Therapy-related acute promyelocytic leukemia. J Clin Oncol 2003, 21(11):2123-2137.
20. Borthakur G., Lin E., Jain N., et al. Survival is poorer in patients with secondary core-binding factor acute myelogenous leukemia compared with de novo core-binding factor leukemia. Cancer 2009, 115(14):3217-3221.
21. Grimwade D., Hills R.K., Moorman A.V., et al. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities amongst 5,876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 2010, 116(3):354-365.
22. Haferlach T., Schoch C., Loffler H., et al. Morphologic dysplasia in de novo acute myeloid leukemia (AML) is related to unfavorable cytogenetics but has no independent prognostic relevance under the conditions of intensive induction therapy: results of a multiparameter analysis from the German AML Cooperative Group studies. J Clin Oncol 2003, 21(2):256-265.
23. Wandt H., Schakel U., Kroschinsky F., et al. MLD according to the WHO classification in AML has no correlation with age and no independent prognostic relevance as analyzed in 1766 patients. Blood 2008, 111(4):1855-1861.
24. Grimwade D. Impact of cytogenetics on clinical outcome in AML. Acute Myelogenous Leukemia 2007, 177-192. Humana Press, New York. J.E. Karp (Ed.).
25. Mrózek K., Heerema N.A., Bloomfield C.D. Cytogenetics in acute leukemia. Blood Rev 2004, 18(2):115-136.
26. Grimwade D., Walker H., Oliver F., et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998, 92(7):2322-2333.
27. Grimwade D., Walker H., Harrison G., et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98(5):1312-1320.
28. Cornelissen J.J., van Putten W.L., Verdonck L.F., et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom?. Blood 2007, 109(9):3658-3666.
29. Burnett A.K. Current controversies: which patients with acute myeloid leukaemia should receive a bone marrow transplantation?-an adult treater's view. Br J Haematol 2002, 118(2):357-364.
30. Burnett A.K., Goldstone A.H., Stevens R.M., et al. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties. Lancet 1998, 351(9104):700-708.
31. Koreth J., Schlenk R., Kopecky K.J., et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. Jama 2009, 301(22):2349-2361.
32. Schoch C., Haase D., Haferlach T., et al. Fifty-one patients with acute myeloid leukemia and translocation t(8;21)(q22;q22): an additional deletion in 9q is an adverse prognostic factor. Leukemia 1996, 10(8):1288-1295.
33. Schlenk R.F., Benner A., Krauter J., et al. Individual patient data-based meta-analysis of patients aged 16 to 60years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2004, 22(18):3741-3750.
34. Appelbaum F.R., Kopecky K.J., Tallman M.S., et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol 2006, 135(2):165-173.
35. Balgobind B.V., Raimondi S.C., Harbott J., et al. Novel prognostic subgroups in childhood 11q23/MLL-rearranged acute myeloid leukemia: results of an international retrospective study. Blood 2009, 114(12):2489-2496.
36. Krauter J., Wagner K., Schafer I., et al. Prognostic factors in adult patients up to 60years old with acute myeloid leukemia and translocations of chromosome band 11q23: individual patient data-based meta-analysis of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol 2009, 27(18):3000-3006.
37. Slovak M.L., Gundacker H., Bloomfield C.D., et al. A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies. Leukemia 2006, 20(7):1295-1297.
38. Soupir C.P., Vergilio J.A., Dal Cin P., et al. Philadelphia chromosome-positive acute myeloid leukemia: a rare aggressive leukemia with clinicopathologic features distinct from chronic myeloid leukemia in myeloid blast crisis. Am J Clin Pathol 2007, 127(4):642-650.
39. Nahi H., Lehmann S., Bengtzen S., et al. Chromosomal aberrations in 17p predict in vitro drug resistance and short overall survival in acute myeloid leukemia. Leuk Lymphoma 2008, 49(3):508-516.
40. Breems D.A., Van Putten W.L., De Greef G.E., et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol 2008, 26(29):4791-4797.
41. De Botton S., Chevret S., Sanz M., et al. Additional chromosomal abnormalities in patients with acute promyelocytic leukaemia (APL) do not confer poor prognosis: results of APL 93 trial. Br J Haematol 2000, 111(3):801-806.
42. Cervera J., Montesinos P., Hernandez-Rivas J.M., et al. Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Haematologica 2010, 95(3):424-431.
43. Marcucci G., Mrózek K., Ruppert A.S., et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol 2005, 23(24):5705-5717.
44. Paschka P., Marcucci G., Ruppert A.S., et al. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol 2006, 24(24):3904-3911.
45. Seifert H., Mohr B., Thiede C., et al. The prognostic impact of 17p (p53) deletion in 2272 adults with acute myeloid leukemia. Leukemia 2009, 23(4):656-663.
46. Bowen D., Groves M.J., Burnett A.K., et al. TP53 gene mutation is frequent in patients with acute myeloid leukemia and complex karyotype, and is associated with very poor prognosis. Leukemia 2009, 23(1):203-206.
47. Cuneo A., Ferrant A., Michaux J.L., et al. Philadelphia chromosome-positive acute myeloid leukemia: cytoimmunologic and cytogenetic features. Haematologica 1996, 81(5):423-427.
48. Yoneda-Kato N., Look A.T., Kirstein M.N., et al. The t(3;5)(q25.1;q34) of myelodysplastic syndrome and acute myeloid leukemia produces a novel fusion gene, NPM-MLF1. Oncogene 1996, 12(2):265-275.
49. Mrózek K., Heinonen K., Lawrence D., et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22; q23) have a superior outcome to patients with other translocations involving band 11q23: a Cancer and Leukemia Group B study. Blood 1997, 90(11):4532-4538.
50. Rubnitz J.E., Raimondi S.C., Tong X., et al. Favorable impact of the t(9;11) in childhood acute myeloid leukemia. J Clin Oncol 2002, 20(9):2302-2309.
51. Schoch C., Schnittger S., Klaus M., et al. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chromosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood 2003, 102(7):2395-2402.
52. Meyer C., Kowarz E., Hofmann J., et al. New insights to the MLL recombinome of acute leukemias. Leukemia 2009, 23(8):1490-1499.
53. Martineau M., Berger R., Lillington D.M., et al. The t(6;11)(q27;q23) translocation in acute leukemia: a laboratory and clinical study of 30 cases. EU Concerted Action 11q23 Workshop participants. Leukemia 1998, 12(5):788-791.
54. Blum W., Mrózek K., Ruppert A.S., et al. Adult de novo acute myeloid leukemia with t(6;11)(q27;q23): results from Cancer and Leukemia Group B Study 8461 and review of the literature. Cancer 2004, 101(6):1420-1427.
55. Casillas J.N., Woods W.G., Hunger S.P., et al. Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 2003, 25(8):594-600.
56. Dreyling M.H., Schrader K., Fonatsch C., et al. MLL and CALM are fused to AF10 in morphologically distinct subsets of acute leukemia with translocation t(10;11): both rearrangements are associated with a poor prognosis. Blood 1998, 91(12):4662-4667.
57. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. Hematol Am Soc Hematol Edu Program 2009, 385-395.
58. Thiede C., Steudel C., Mohr B., et al. Analysis of FLT3-activating mutations in 979 patients with acute myelogenous leukemia: association with FAB subtypes and identification of subgroups with poor prognosis. Blood 2002, 99(12):4326-4335.
59. Gilliland D.G., Griffin J.D. The roles of FLT3 in hematopoiesis and leukemia. Blood 2002, 100(5):1532-1542.
60. Kottaridis P.D., Gale R.E., Linch D.C. Flt3 mutations and leukaemia. Br J Haematol 2003, 122(4):523-538.
61. Breitenbuecher F., Schnittger S., Grundler R., et al. Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor. Blood 2009, 113(17):4074-4077.
62. Yamamoto Y., Kiyoi H., Nakano Y., et al. Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 2001, 97(8):2434-2439.
63. Abu-Duhier F.M., Goodeve A.C., Wilson G.A., et al. Identification of novel FLT-3 Asp835 mutations in adult acute myeloid leukaemia. Br J Haematol 2001, 113(4):983-988.
64. Mead A.J., Linch D.C., Hills R.K., et al. FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia. Blood 2007, 110(4):1262-1270.
65. Noguera N.I., Breccia M., Divona M., et al. Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol. Leukemia 2002, 16(11):2185-2189.
66. Arrigoni P., Beretta C., Silvestri D., et al. FLT3 internal tandem duplication in childhood acute myeloid leukaemia: association with hyperleucocytosis in acute promyelocytic leukaemia. Br J Haematol 2003, 120(1):89-92.
67. Gale R.E., Hills R., Pizzey A.R., et al. Relationship between FLT3 mutation status, biologic characteristics, and response to targeted therapy in acute promyelocytic leukemia. Blood 2005, 106(12):3768-3776.
68. Kottaridis P.D., Gale R.E., Frew M.E., et al. The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials. Blood 2001, 98(6):1752-1759.
69. Frohling S., Schlenk R.F., Breitruck J., et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood 2002, 100(13):4372-4380.
70. Kiyoi H., Naoe T., Yokota S., et al. Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 1997, 11(9):1447-1452.
71. Schnittger S., Schoch C., Dugas M., et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood 2002, 100(1):59-66.
72. Whitman S.P., Archer K.J., Feng L., et al. Absence of the wild-type allele predicts poor prognosis in adult de novo acute myeloid leukemia with normal cytogenetics and the internal tandem duplication of FLT3: a Cancer and Leukemia Group B study. Cancer Res 2001, 61(19):7233-7239.
73. Gale R.E., Green C., Allen C., et al. The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia. Blood 2008, 111(5):2776-2784.
74. Fitzgibbon J., Smith L.L., Raghavan M., et al. Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias. Cancer Res 2005, 65(20):9152-9154.
75. Whitman S.P., Ruppert A.S., Radmacher M.D., et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood 2008, 111(3):1552-1559.
76. Mead A.J., Gale R.E., Hills R.K., et al. Conflicting data on the prognostic significance of FLT3/TKD mutations in acute myeloid leukemia might be related to the incidence of biallelic disease. Blood 2008, 112(2):444-445. author reply 445.
77. Bacher U., Haferlach C., Kern W., et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients. Blood 2008, 111(5):2527-2537.
78. Rau R., Brown P. Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 2009, 27(4):171-181.
79. Falini B., Nicoletti I., Bolli N., et al. Translocations and mutations involving the nucleophosmin (NPM1) gene in lymphomas and leukemias. Haematologica 2007, 92(4):519-532.
80. Verhaak R.G., Goudswaard C.S., van Putten W., et al. Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance. Blood 2005, 106(12):3747-3754.
81. Döhner K., Schlenk R.F., Habdank M., et al. Mutant nucleophosmin (NPM1) predicts favorable prognosis in younger adults with acute myeloid leukemia and normal cytogenetics: interaction with other gene mutations. Blood 2005, 106(12):3740-3746.
82. Schlenk R.F., Döhner K., Krauter J., et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1909-1918.
83. Radomska H.S., Huettner C.S., Zhang P., et al. CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 1998, 18(7):4301-4314.
84. Liu H., Keefer J.R., Wang Q.F., et al. Reciprocal effects of C/EBPalpha and PKCdelta on JunB expression and monocytic differentiation depend upon the C/EBPalpha basic region. Blood 2003, 101(10):3885-3892.
85. Lin L.I., Chen C.Y., Lin D.T., et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. Clin Cancer Res 2005, 11(4):1372-1379.
86. Dufour A., Schneider F., Metzeler K.H., et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol 2010, 28(4):570-577.
87. Pabst T., Eyholzer M., Haefliger S., et al. Somatic CEBPA mutations are a frequent second event in families with germline CEBPA mutations and familial acute myeloid leukemia. J Clin Oncol 2008, 26(31):5088-5093.
88. Smith M.L., Cavenagh J.D., Lister T.A., et al. Mutation of CEBPA in familial acute myeloid leukemia. N Engl J Med 2004, 351(23):2403-2407.
89. Preudhomme C., Sagot C., Boissel N., et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA). Blood 2002, 100(8):2717-2723.
90. van Waalwijk van Doorn-Khosrovani S.B., Erpelinck C., Meijer J., et al. Biallelic mutations in the CEBPA gene and low CEBPA expression levels as prognostic markers in intermediate-risk AML. Hematol J 2003, 4(1):31-40.
91. Frohling S., Schlenk R.F., Stolze I., et al. CEBPA mutations in younger adults with acute myeloid leukemia and normal cytogenetics: prognostic relevance and analysis of cooperating mutations. J Clin Oncol 2004, 22(4):624-633.
92. Wouters B.J., Lowenberg B., Erpelinck-Verschueren C.A., et al. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood 2009, 113(13):3088-3091.
93. Pabst T., Eyholzer M., Fos J., et al. Heterogeneity within AML with CEBPA mutations; only CEBPA double mutations, but not single CEBPA mutations are associated with favourable prognosis. Br J Cancer 2009, 100(8):1343-1346.
94. Renneville A., Boissel N., Gachard N., et al. The favorable impact of CEBPA mutations in patients with acute myeloid leukemia is only observed in the absence of associated cytogenetic abnormalities and FLT3 internal duplication. Blood 2009, 113(21):5090-5093.
95. Green C.L., Koo K.K., Hills R.K., et al. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations. J Clin Oncol 2010, 28(16):2739-2747.
96. Gari M., Goodeve A., Wilson G., et al. c-kit proto-oncogene exon 8 in-frame deletion plus insertion mutations in acute myeloid leukaemia. Br J Haematol 1999, 105(4):894-900.
97. Goemans B., Zwaan C.M., Miller M. Incidence and prognostic significance of c-kit exon 8 and 17 mutations in pediatric AML. Erasmus workshop on molecular therapeutics in acute leukaemia 2003, 91. Erasmus MC, Rotterdam. B. Lowenberg, R. Pieters, P. Sonneveld, I. Touw, J.J. van Dongen (Eds.).
98. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107(9):3463-3468.
99. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107(5):1791-1799.
100. Mardis E.R., Ding L., Dooling D.J., et al. Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 2009, 361(11):1058-1066.
101. Chou W.C., Hou H.A., Chen C.Y., et al. Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation. Blood 2010, 115(14):2749-2754.
102. Ho P.A., Alonzo T.A., Kopecky K.J., et al. Molecular alterations of the IDH1 gene in AML: a Children's Oncology Group and Southwest Oncology Group study. Leukemia 2010, 24(5):909-913.
103. Thol F., Damm F., Wagner K., et al. Prognostic impact of IDH2 mutations in cytogenetically normal acute myeloid leukemia. Blood 2010, 116(4):614-616.
104. Ward P.S., Patel J., Wise D.R., et al. The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 2010, 17(3):225-234.
105. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 mutations in gliomas. N Engl J Med 2009, 360(8):765-773.
106. Marcucci G., Maharry K., Wu Y.Z., et al. IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2010, 28(14):2348-2355.
107. Schnittger S., Haferlach C., Ulke M., et al. IDH1 mutations are detected in 6.6% of 1414 AML patients and are associated with intermediate risk karyotype and unfavorable prognosis in adults younger than 60 years and unmutated NPM1 status. Blood 2010 Aug 30, [Electronic publication ahead of print].
108. Paschka P., Marcucci G., Ruppert A.S., et al. Wilms' tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2008, 26(28):4595-4602.
109. Virappane P., Gale R., Hills R., et al. Mutation of the Wilms' tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008, 26(33):5429-5435.
110. Gaidzik V.I., Schlenk R.F., Moschny S., et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009, 113(19):4505-4511.
111. Schnittger S., Kinkelin U., Schoch C., et al. Screening for MLL tandem duplication in 387 unselected patients with AML identify a prognostically unfavorable subset of AML. Leukemia 2000, 14(5):796-804.
112. Döhner K., Tobis K., Ulrich R., et al. Prognostic significance of partial tandem duplications of the MLL gene in adult patients 16 to 60years old with acute myeloid leukemia and normal cytogenetics: a study of the Acute Myeloid Leukemia Study Group Ulm. J Clin Oncol 2002, 20(15):3254-3261.
113. Tang J.L., Hou H.A., Chen C.Y., et al. AML1/RUNX1 mutations in 470 adult patients with de novo acute myeloid leukemia: prognostic implication and interaction with other gene alterations. Blood 2009, 114(26):5352-5361.
114. Abdel-Wahab O., Mullally A., Hedvat C., et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 2009, 114(1):144-147.
115. Mullighan C.G. TET2 mutations in myelodysplasia and myeloid malignancies. Nat Genet 2009, 41(7):766-767.
116. Tefferi A., Lim K.H., Levine R. Mutation in TET2 in myeloid cancers. N Engl J Med 2009, 361(11):1117. author reply 1117-1118.
117. Reindl C., Quentmeier H., Petropoulos K., et al. CBL exon 8/9 mutants activate the FLT3 pathway and cluster in core binding factor/11q deletion acute myeloid leukemia/myelodysplastic syndrome subtypes. Clin Cancer Res 2009, 15(7):2238-2247.
118. Loh M., Reynolds M.G., Vattikuti S., et al. Incidence and prognostic significance of PTPN11 mutations in pediatric acute myelogenous leukaemia-results from Children's Cancer Group Trials 2941 and 2961. Blood 2003, 102(11(S1)):376a.
119. Baldus C.D., Tanner S.M., Ruppert A.S., et al. BAALC expression predicts clinical outcome of de novo acute myeloid leukemia patients with normal cytogenetics: a Cancer and Leukemia Group B Study. Blood 2003, 102(5):1613-1618.
120. Santamaria C, Chillon MC, Garcia-Sanz R, et al. BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML). Ann Hematol; 89(5): 453-458.
121. Langer C., Marcucci G., Holland K.B., et al. Prognostic importance of MN1 transcript levels, and biologic insights from MN1-associated gene and microRNA expression signatures in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2009, 27(19):3198-3204.
122. Heuser M., Beutel G., Krauter J., et al. High meningioma 1 (MN1) expression as a predictor for poor outcome in acute myeloid leukemia with normal cytogenetics. Blood 2006, 108(12):3898-3905.
123. Marcucci G., Maharry K., Whitman S.P., et al. High expression levels of the ETS-related gene, ERG, predict adverse outcome and improve molecular risk-based classification of cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B Study. J Clin Oncol 2007, 25(22):3337-3343.
124. Mrózek K., Marcucci G., Paschka P., et al. Clinical relevance of mutations and gene-expression changes in adult acute myeloid leukemia with normal cytogenetics: are we ready for a prognostically prioritized molecular classification?. Blood 2007, 109(2):431-448.
125. Lugthart S., van Drunen E., van Norden Y., et al. High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated. Blood 2008, 111(8):4329-4337.
126. Groschel S., Lugthart S., Schlenk R.F., et al. High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities. J Clin Oncol 2010, 28(12):2101-2107.
127. Bullinger L., Döhner K., Bair E., et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004, 350(16):1605-1616.
128. Metzeler K.H., Hummel M., Bloomfield C.D., et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood 2008, 112(10):4193-4201.
129. Wouters B.J., Lowenberg B., Delwel R. A decade of genome-wide gene expression profiling in acute myeloid leukemia: flashback and prospects. Blood 2009, 113(2):291-298.
130. Marie J.P. Drug resistance in hematologic malignancies. Curr Opin Oncol 2001, 13(6):463-469.
131. Beck W.T., Grogan T.M., Willman C.L., et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996, 56(13):3010-3020.
132. Wuchter C., Leonid K., Ruppert V., et al. Clinical significance of P-glycoprotein expression and function for response to induction chemotherapy, relapse rate and overall survival in acute leukemia. Haematologica 2000, 85(7):711-721.
133. Laupeze B., Amiot L., Drenou B., et al. High multidrug resistance protein activity in acute myeloid leukaemias is associated with poor response to chemotherapy and reduced patient survival. Br J Haematol 2002, 116(4):834-838.
134. Tsuji K., Motoji T., Sugawara I., et al. Significance of lung resistance-related protein in the clinical outcome of acute leukaemic patients with reference to P-glycoprotein. Br J Haematol 2000, 110(2):370-378.
135. Volk E.L., Farley K.M., Wu Y., et al. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance. Cancer Res 2002, 62(17):5035-5040.
136. Schaich M., Soucek S., Thiede C., et al. MDR1 and MRP1 gene expression are independent predictors for treatment outcome in adult acute myeloid leukaemia. Br J Haematol 2005, 128(3):324-332.
137. Huh H.J., Park C.J., Jang S., et al. Prognostic significance of multidrug resistance gene 1 (MDR1), multidrug resistance-related protein (MRP) and lung resistance protein (LRP) mRNA expression in acute leukemia. J Korean Med Sci 2006, 21(2):253-258.
138. Cheson B.D., Bennett J.M., Kopecky K.J., et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol 2003, 21(24):4642-4649.
139. Burnett A., Hills R.K., Wheatley K., et al. A sensitive risk score for directing treatment in younger patients with AML [abstract]. Blood 2006, 108:10.
140. Kern W., Haferlach T., Schoch C., et al. Early blast clearance by remission induction therapy is a major independent prognostic factor for both achievement of complete remission and long-term outcome in acute myeloid leukemia: data from the German AML Cooperative Group (AMLCG) 1992 Trial. Blood 2003, 101(1):64-70.
141. Sanz M.A., Grimwade D., Tallman M.S., et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2009, 113(9):1875-1891.
142. Marcucci G., Mrózek K., Ruppert A.S., et al. Abnormal cytogenetics at date of morphologic complete remission predicts short overall and disease-free survival, and higher relapse rate in adult acute myeloid leukemia: results from Cancer and Leukemia Group B study 8461. J Clin Oncol 2004, 22(12):2410-2418.
143. Balleisen S., Kuendgen A., Hildebrandt B., et al. Prognostic relevance of achieving cytogenetic remission in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome following induction chemotherapy. Leuk Res 2009, 33(9):1189-1193.
144. Campana D., Pui C.H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood 1995, 85(6):1416-1434.
145. Yin J.A., Grimwade D. Minimal residual disease evaluation in acute myeloid leukaemia. Lancet 2002, 360(9327):160-162.
146. Freeman S.D., Jovanovic J.V., Grimwade D. Development of minimal residual disease-directed therapy in acute myeloid leukemia. Semin Oncol 2008, 35(4):388-400.
147. Cilloni D., Renneville A., Hermitte F., et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study. J Clin Oncol 2009, 27(31):5195-5201.
148. Schnittger S., Kern W., Tschulik C., et al. Minimal residual disease levels assessed by NPM1 mutation-specific RQ-PCR provide important prognostic information in AML. Blood 2009, 114(11):2220-2231.
149. Venditti A., Buccisano F., Del Poeta G., et al. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood 2000, 96(12):3948-3952.
150. San Miguel J.F., Vidriales M.B., Lopez-Berges C., et al. Early immunophenotypical evaluation of minimal residual disease in acute myeloid leukemia identifies different patient risk groups and may contribute to postinduction treatment stratification. Blood 2001, 98(6):1746-1751.
151. Maurillo L., Buccisano F., Del Principe M.I., et al. Toward optimization of postremission therapy for residual disease-positive patients with acute myeloid leukemia. J Clin Oncol 2008, 26(30):4944-4951.
152. Rubnitz J.E., Inaba H., Dahl G., et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol 2010, 11(6):543-552.
153. Grimwade D, Tallman M. Should minimal residual disease monitoring be the standard of care for all patients with acute promyelocytic leukemia? Leuk Res 2010 Jul 29. [Electronic publication ahead of print].
154. Gabert J., Beillard E., van der Velden V.H., et al. Standardization and quality control studies of 'real-time' quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia-a Europe Against Cancer program. Leukemia 2003, 17(12):2318-2357.
155. Milligan D.W., Grimwade D., Cullis J.O., et al. Guidelines on the management of acute myeloid leukaemia in adults. Br J Haematol 2006, 135(4):450-474.
156. Grimwade D., Jovanovic J.V., Hills R.K., et al. Prospective minimal residual disease monitoring to predict relapse of acute promyelocytic leukemia and to direct pre-emptive arsenic trioxide therapy. J Clin Oncol 2009, 27(22):3650-3658.
157. Lo Coco F., Diverio D., Avvisati G., et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999, 94(7):2225-2229.
158. Esteve J., Escoda L., Martin G., et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007, 21(3):446-452.
159. Gorello P., Cazzaniga G., Alberti F., et al. Quantitative assessment of minimal residual disease in acute myeloid leukemia carrying nucleophosmin (NPM1) gene mutations. Leukemia 2006, 20(6):1103-1108.
160. Chou W.C., Tang J.L., Wu S.J., et al. Clinical implications of minimal residual disease monitoring by quantitative polymerase chain reaction in acute myeloid leukemia patients bearing nucleophosmin (NPM1) mutations. Leukemia 2007, 21(5):998-1004.
161. Ommen H.B., Schnittger S., Jovanovic J.V., et al. Strikingly different molecular relapse kinetics in NPM1c, PML-RARA, RUNX1-RUNX1T1, and CBFB-MYH11 acute myeloid leukemias. Blood 2010, 115(2):198-205.
162. Falini B., Sportoletti P., Martelli M.P. Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 2009, 21(6):573-581.
163. Tallman M., Rowe J.M. Long-term follow-up and potential for cure in acute promyelocytic leukaemia. Best Pract Res Clin Haematol 2003, 16:535-543.
164. Liddiard K., Hills R., Burnett A.K., et al. OGG1 is a novel prognostic indicator in acute myeloid leukaemia. Oncogene 2010, 29(13):2005-2012.
165. Wieser R., Scheideler M., Hackl H., et al. microRNAs in acute myeloid leukemia: expression patterns, correlations with genetic and clinical parameters, and prognostic significance. Genes Chromosom Cancer 2010, 49(3):193-203.
166. Garzon R., Volinia S., Liu C.G., et al. MicroRNA signatures associated with cytogenetics and prognosis in acute myeloid leukemia. Blood 2008, 111(6):3183-3189.
167. Marcucci G., Radmacher M.D., Maharry K., et al. MicroRNA expression in cytogenetically normal acute myeloid leukemia. N Engl J Med 2008, 358(18):1919-1928.
168. Tiu R.V., Gondek L.P., O'Keefe C.L., et al. New lesions detected by single nucleotide polymorphism array-based chromosomal analysis have important clinical impact in acute myeloid leukemia. J Clin Oncol 2009, 27(31):5219-5226.
169. Bullinger L., Ehrich M., Döhner K., et al. Quantitative DNA methylation predicts survival in adult acute myeloid leukemia. Blood 2010, 115(3):636-642.
170. Figueroa M.E., Lugthart S., Li Y., et al. DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 2010, 17(1):13-27.
171. Yan Y., Wieman E.A., Guan X., et al. Autonomous growth potential of leukemia blast cells is associated with poor prognosis in human acute leukemias. J Hematol Oncol 2009, 2:51.
172. Pearce D.J., Taussig D., Zibara K., et al. AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 2006, 107(3):1166-1173.
173. Majeti R., Chao M.P., Alizadeh A.A., et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell 2009, 138(2):286-299.
174. Schnittger S., Schoch C., Kern W., et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005, 106(12):3733-3739.
175. Döhner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
176. Schlenk R.F., Frohling S., Hartmann F., et al. Phase III study of all-trans retinoic acid in previously untreated patients 61years or older with acute myeloid leukemia. Leukemia 2004, 18(11):1798-1803.
177. Burnett A.K., Hills R.K., Green C., et al. The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: overall results and results in genotypic subgroups defined by mutations in NPM1, FLT3, and CEBPA. Blood 2010, 115(5):948-956.
178. Whitman S.P., Ruppert A.S., Marcucci G., et al. Long-term disease-free survivors with cytogenetically normal acute myeloid leukemia and MLL partial tandem duplication: a Cancer and Leukemia Group B study. Blood 2007, 109(12):5164-5167.
179. Meschinchi S., Arceci R.J., Sanders J.E., et al. Role of allogeneic stem cell transplantation in FLT3/ITD-positive AML. Blood 2006, 108:400-401.
180. Gale R., Hills R., Wheatley K., et al. Response: still a need for more robust evidence that FLT3/ITD status should influence he decision to proceed to transplantation in AML patients. Blood 2007, 109:2265.
181. Gale R.E., Hills R., Kottaridis P.D., et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood 2005, 106(10):3658-3665.
182. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010 Nov 10, [Epub ahead of print].